Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company focused on metabolic health, has announced its participation in three upcoming healthcare investment conferences in September 2024:
- Morgan Stanley conference on September 6 (1x1 meetings)
- Cantor Global Healthcare Conference on September 19 (presentation and 1x1 meetings)
- Bank of America World Medical Innovation Forum on September 24 (panel and 1x1 meetings)
These events provide Skye with opportunities to present its research and engage with investors. Webcasts of available presentations will be accessible on Skye's website, offering wider access to the company's updates and progress in the field of metabolic health therapeutics.
Skye Bioscience (Nasdaq: SKYE), un'azienda biopharmaceutica in fase clinica focalizzata sulla salute metabolica, ha annunciato la sua partecipazione a tre prossimi conferenze di investimento nel settore sanitario nel settembre 2024:
- Conferenza Morgan Stanley il 6 settembre (incontri 1x1)
- Conferenza Cantor Global Healthcare il 19 settembre (presentazione e incontri 1x1)
- Forum per l'Innovazione Medica Mondiale di Bank of America il 24 settembre (panel e incontri 1x1)
Questi eventi offrono a Skye l'opportunità di presentare la sua ricerca e interagire con gli investitori. I webcast delle presentazioni disponibili saranno accessibili sul sito web di Skye, offrendo un accesso più ampio agli aggiornamenti e ai progressi dell'azienda nel campo delle terapie per la salute metabolica.
Skye Bioscience (Nasdaq: SKYE), una empresa biofarmacéutica en etapa clínica centrada en la salud metabólica, ha anunciado su participación en tres próximas conferencias de inversión en salud en septiembre de 2024:
- Conferencia de Morgan Stanley el 6 de septiembre (reuniones 1x1)
- Conferencia Cantor Global Healthcare el 19 de septiembre (presentación y reuniones 1x1)
- Foro de Innovación Médica Mundial de Bank of America el 24 de septiembre (panel y reuniones 1x1)
Estos eventos brindan a Skye oportunidades para presentar su investigación e interactuar con los inversores. Las transmisiones web de las presentaciones disponibles estarán accesibles en el sitio web de Skye, ofreciendo un acceso más amplio a las actualizaciones y avances de la empresa en el campo de las terapias de salud metabólica.
스카이 바이오사이언스 (나스닥: SKYE)는 대사 건강에 중점을 둔 임상 단계의 생명공학 기업으로, 2024년 9월에 진행될 세 개의 의료 투자 컨퍼런스에 참가할 예정이라고 발표했습니다:
- 모건 스탠리 회의 9월 6일 (1대1 미팅)
- 칸토 글로벌 헬스케어 컨퍼런스 9월 19일 (발표 및 1대1 미팅)
- 뱅크 오브 아메리카 세계 의료 혁신 포럼 9월 24일 (패널 및 1대1 미팅)
이러한 이벤트는 스카이가 연구 결과를 발표하고 투자자와 소통할 기회를 제공합니다. 제공되는 발표의 웹캐스트는 스카이 웹사이트에서 확인할 수 있으며, 대사 건강 치료 분야에서 회사의 업데이트와 진행 사항에 대한 더 넓은 접근을 제공합니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise biopharmaceutique en phase clinique axée sur la santé métabolique, a annoncé sa participation à trois prochaines conférences d'investissement en santé en septembre 2024 :
- Conférence Morgan Stanley le 6 septembre (réunions 1x1)
- Conférence Cantor Global Healthcare le 19 septembre (présentation et réunions 1x1)
- Forum mondial sur l'innovation médicale de Bank of America le 24 septembre (panel et réunions 1x1)
Ces événements offrent à Skye des opportunités de présenter ses recherches et d'interagir avec les investisseurs. Les webdiffusions des présentations disponibles seront accessibles sur le site Web de Skye, offrant un accès plus large aux mises à jour et aux progrès de l'entreprise dans le domaine des thérapeutiques de la santé métabolique.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf metabolische Gesundheit konzentriert, hat seine Teilnahme an drei bevorstehenden Gesundheitsinvestitionskonferenzen im September 2024 angekündigt:
- Morgan Stanley Konferenz am 6. September (1x1 Meetings)
- Cantor Global Healthcare Conference am 19. September (Präsentation und 1x1 Meetings)
- Bank of America World Medical Innovation Forum am 24. September (Panel und 1x1 Meetings)
Diese Veranstaltungen bieten Skye die Möglichkeit, ihre Forschung zu präsentieren und mit Investoren in Kontakt zu treten. Die Webcasts der verfügbaren Präsentationen werden auf der Website von Skye zugänglich sein, um einen breiteren Zugang zu den Aktualisierungen und Fortschritten des Unternehmens im Bereich der therapeutischen Ansätze zur metabolischen Gesundheit zu ermöglichen.
- None.
- None.
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:
- Morgan Stanley, Friday, September 6, 1x1 meetings (New York)
- Cantor Global Healthcare Conference, Thursday, September 19, 8:35 am ET, presentation + 1x1 meetings (New York)
- Bank of America World Medical Innovation Forum, Tuesday, September 24, panel + 1x1 meetings (Boston)
Available webcasts will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye started a Phase 2 clinical trial in obesity in August 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: https://www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and the therapeutic potential of our therapeutic candidates. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
What conferences will Skye Bioscience (SKYE) attend in September 2024?
When is Skye Bioscience (SKYE) presenting at the Cantor Global Healthcare Conference?
Will Skye Bioscience (SKYE) offer webcasts of their conference presentations?
What is the focus of Skye Bioscience (SKYE) as a company?
